To help educate and raise awareness on this rare disease, Catherine Jackson, Senior Director of Patient Engagement & Advocacy at Mallinckrodt has interviewed John Malcolmson, Executive Director of Scleroderma Canada and Scleroderma Society of Ontario. […]
Creativity and innovation are born of a wealth of different perspectives and perceptions—and we’re celebrating some of that wealth this month. In honor of AAPI Heritage Month, we’ve asked one of our Asian American and […]
As with the heinous racially motivated crimes of the recent past, I strongly condemn all acts of racism, hatred and personal stereotyping in any form. At Mallinckrodt, we are committed to diversity, equity and inclusion, and embrace the diverse experiences, cultures and views of our employees as a great differentiator and enduring strength for our organization.
2020 has highlighted the systemic injustice that persists due to institutional inequity in our country. As a patient-centric biopharmaceutical company, we must address the health disparities that result from this continuing inequity. The pandemic has underscored this harsh reality, as people of color, particularly African Americans, endure higher levels of illness and death than White Americans due to the COVID-19 virus.
